BMC Pharmacology and Toxicology is calling for submissions to our Collection on Neonatal and pediatric drug development and safety.

The recent surge of attention to neonatal and pediatric medication is mainly due to the recognition of distinct pharmacokinetics and pharmacodynamics in infants and children compared to adults. These variations can have a substantial impact on the safety and efficacy of medications. Insufficient clinical trials and limited access to licensed drugs for infants and kids can lead to less-than-ideal therapeutic choices and raise the possibility of adverse drug reactions. Hence, it is crucial to conduct in-depth research specifically designed for these vulnerable populations. Through this Collection, we aim to gather studies that further our knowledge of medication development and safety in neonatal and pediatric healthcare while promoting better clinical outcomes.

Continued exploration in this area is essential as advancements in drug formulation, delivery systems, and regulatory frameworks gain prominence. Recent initiatives, such as the establishment of pediatric research networks and the implementation of incentives for drug development in children, have made strides in filling these gaps. However, there remains an urgent need for comprehensive studies that not only assess the safety and efficacy of drugs but also consider the long-term effects of treatment in pediatric populations. By fostering collaboration among researchers, clinicians, and regulatory bodies, we can further enhance drug development processes that prioritize the health and safety of our youngest patients.

We encourage articles on various aspects of basic research, clinical trials, and health care.

Potential topics include, but are not limited to:

Innovative drug delivery systems for neonates

Assessing adverse drug reactions in pediatric populations

Strategies for enhancing drug safety in neonatal healthcare

Regulatory frameworks for pediatric drug development

Drug development and evaluation by pharmacokinetics, pharmacodynamics, and Population pharmacokinetics

Health care challenges in low and middle-income countries

Early drug exposure and health care of neonates, children, and adolescents

This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

BMC Pharmacology and Toxicology is calling for submissions for the Collection on Small molecule therapy.

Small molecule therapy encompasses a diverse range of pharmacological agents designed to modulate biological processes at the molecular level. These compounds have revolutionized the treatment landscape for various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. The ongoing exploration of small molecules, their mechanisms of action, and their interactions with cellular pathways has opened new avenues for therapeutic development. This Collection aims to highlight recent advancements and innovative strategies in small molecule therapy, focusing on the design, synthesis, and application of these agents to treat various diseases.

The development of highly specific small molecule therapeutic compounds has improved treatment efficacy while minimizing toxicity, and recent breakthroughs in drug delivery systems and formulation techniques have enabled targeted therapies that maximize therapeutic benefit while reducing side effects. Additionally, advances in computational methods, including machine learning and AI-guided drug design, when accompanied by real-world validation of molecular targets, are a promising avenue of research in this field.

To showcase advances in the development of small molecule therapies, topics for this collection include but are not limited to:

Target specificity in small molecule design

Assessment of pre-clinical and clinical toxicity and long-term effects

Drug-drug interactions in small molecule therapy

Innovations in drug delivery and formulation

Computational and AI-guided small molecule drug design

Validation of in silico studies with in vitro and in vivo data

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.